290 Heart failure outcomes

tion was defined by a left ventricular ejection fraction (LVEF ≤ 40%). In 54 patients (17.7%) had reduced Left Ventricular Ejection Function (LVEF ≤ 40%). The patients with reduced LVEF had more comorbidities compared with normal function: Charlson index 4.3±1.9 vs. 3.4±1.8, P = 0.001; Karnosky index 45±19 vs. 61±18, P = 0.001), Frailty 25.9% vs. 11.6%, P= 0.006, worse Logistic EuroSCORE 29.7±17 vs. 17±10, P < 0.001, were more often males (55.6% vs. 37.5%, P= 0.014, more symptomatic (NYHA class IV 64.8% vs. 26.3%, p< 0.001, were younger (77±7.4 vs. 79±6.2, P = 0.005) and had a higher prevalence of prior Coronary Artery Disease (55.6% vs. 34.7%, p = 0.004). No difference was observed between the 2 groups in in-hospital mortality (7.4% vs. 4.4%, P= 0.351), or late mortality (15.7% vs. 13.3%, p= 0.658) In 34 of the 54 patients who had reduced LVEF showing an improvement in ejection fraction, 35± 5t o 53 ±7 P = 0.006. Conclusions: In patients with severe aortic stenosis and depressed LV systolic function, TAVI is associated with better LVEF recovery and the immediate and long-term outcome after TAVI did no differ between patients with an impaired and preserved LVEF.